FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996716984> ?p ?o ?g. }

• W1996716984 endingPage "196" @default.
• W1996716984 startingPage "185" @default.
• W1996716984 abstract "The γ-carboxyglutamic acid (Gla) domains of the vitamin K-dependent blood coagulation proteins contain 10 highly conserved Gla residues within the first 33 residues, but factor IX is unique in possessing 2 additional Gla residues at positions 36 and 40. To determine their importance, factor IX species lacking these Gla residues were isolated from heterologously expressed human factor IX. Using ion-exchange chromatography, peptide mapping, mass spectrometry, and N-terminal sequencing, we have purified and identified two partially carboxylated recombinant factor IX species; factor IX/γ40E is uncarboxylated at residue 40 and factor IX/γ36,40E is uncarboxylated at both residues 36 and 40. These species were compared with the fully y-carboxylated recombinant factor IX, unfractionated recombinant factor IX, and plasma-derived factor IX. As monitored by anti-factor IX:Ca(II)-specific antibodies and by the quenching of intrinsic fluorescence, all these factor IX species underwent the Ca(II)-induced conformational transition required for phospholipid membrane binding and bound equivalently to phospholipid vesicles composed of phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. Endothelial cell binding was also similar in all species, with half-maximal inhibition of the binding of 125I-labeled plasma-derived factor IX at concentrations of 2–6 nM. Functionally, factor IX/γ36,40E and factor IX/γ40E were similar to fully γ-carboxylated recombinant factor IX and plasma-derived factor IX in their coagulant activity and in their ability to participate in the activation of factor X in the tenase complex both with synthetic phospholipid vesicles and activated platelets. However, Gla 36 and Gla 40 represent part of the epitope targeted by anti-factor IX:Mg(II)-specific antibodies because these antibodies bound factor IX preferentially to factor LX/γ36,40E and factor IX/γ40E. These results demonstrate that the γ-carboxylation of glutamic acid residues 36 and 40 in human factor IX is not required for any function of factor IX examined." @default.
• W1996716984 created "2016-06-24" @default.
• W1996716984 creator A5002751673 @default.
• W1996716984 creator A5011095449 @default.
• W1996716984 creator A5024864443 @default.
• W1996716984 creator A5030338763 @default.
• W1996716984 creator A5031862419 @default.
• W1996716984 creator A5032864504 @default.
• W1996716984 creator A5037056994 @default.
• W1996716984 creator A5066321804 @default.
• W1996716984 date "1997-01-01" @default.
• W1996716984 modified "2023-10-07" @default.
• W1996716984 title "γ-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function" @default.
• W1996716984 cites W1487857339 @default.
• W1996716984 cites W1492871881 @default.
• W1996716984 cites W1495366495 @default.
• W1996716984 cites W1499326065 @default.
• W1996716984 cites W1501889443 @default.
• W1996716984 cites W1519472851 @default.
• W1996716984 cites W1524957948 @default.
• W1996716984 cites W1537891220 @default.
• W1996716984 cites W1566210470 @default.
• W1996716984 cites W1567503172 @default.
• W1996716984 cites W1586727171 @default.
• W1996716984 cites W1591018620 @default.
• W1996716984 cites W1595472253 @default.
• W1996716984 cites W1638703855 @default.
• W1996716984 cites W1647160467 @default.
• W1996716984 cites W1735160523 @default.
• W1996716984 cites W1745001432 @default.
• W1996716984 cites W1748714271 @default.
• W1996716984 cites W1782728159 @default.
• W1996716984 cites W1786757590 @default.
• W1996716984 cites W1969980439 @default.
• W1996716984 cites W1971187273 @default.
• W1996716984 cites W1980284757 @default.
• W1996716984 cites W1984724591 @default.
• W1996716984 cites W1985342306 @default.
• W1996716984 cites W1985991869 @default.
• W1996716984 cites W1994696018 @default.
• W1996716984 cites W2032279957 @default.
• W1996716984 cites W2036019800 @default.
• W1996716984 cites W2041349540 @default.
• W1996716984 cites W2048182696 @default.
• W1996716984 cites W2055314772 @default.
• W1996716984 cites W2055843557 @default.
• W1996716984 cites W2059603894 @default.
• W1996716984 cites W2061216302 @default.
• W1996716984 cites W2076095425 @default.
• W1996716984 cites W2085193664 @default.
• W1996716984 cites W2089561791 @default.
• W1996716984 cites W2097993282 @default.
• W1996716984 cites W2123259277 @default.
• W1996716984 cites W2154490052 @default.
• W1996716984 cites W2160833147 @default.
• W1996716984 cites W2165177447 @default.
• W1996716984 cites W2333330110 @default.
• W1996716984 cites W2344022727 @default.
• W1996716984 cites W2401223474 @default.
• W1996716984 cites W2409014483 @default.
• W1996716984 cites W2418477989 @default.
• W1996716984 cites W305846754 @default.
• W1996716984 cites W4246266059 @default.
• W1996716984 doi "https://doi.org/10.1002/pro.5560060121" @default.
• W1996716984 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2143515" @default.
• W1996716984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9007991" @default.
• W1996716984 hasPublicationYear "1997" @default.
• W1996716984 type Work @default.
• W1996716984 sameAs 1996716984 @default.
• W1996716984 citedByCount "49" @default.
• W1996716984 countsByYear W19967169842012 @default.
• W1996716984 countsByYear W19967169842013 @default.
• W1996716984 countsByYear W19967169842014 @default.
• W1996716984 countsByYear W19967169842015 @default.
• W1996716984 countsByYear W19967169842016 @default.
• W1996716984 countsByYear W19967169842017 @default.
• W1996716984 countsByYear W19967169842019 @default.
• W1996716984 countsByYear W19967169842020 @default.
• W1996716984 countsByYear W19967169842021 @default.
• W1996716984 countsByYear W19967169842022 @default.
• W1996716984 crossrefType "journal-article" @default.
• W1996716984 hasAuthorship W1996716984A5002751673 @default.
• W1996716984 hasAuthorship W1996716984A5011095449 @default.
• W1996716984 hasAuthorship W1996716984A5024864443 @default.
• W1996716984 hasAuthorship W1996716984A5030338763 @default.
• W1996716984 hasAuthorship W1996716984A5031862419 @default.
• W1996716984 hasAuthorship W1996716984A5032864504 @default.
• W1996716984 hasAuthorship W1996716984A5037056994 @default.
• W1996716984 hasAuthorship W1996716984A5066321804 @default.
• W1996716984 hasBestOaLocation W19967169842 @default.
• W1996716984 hasConcept C104317684 @default.
• W1996716984 hasConcept C118552586 @default.
• W1996716984 hasConcept C130316041 @default.
• W1996716984 hasConcept C15744967 @default.
• W1996716984 hasConcept C185592680 @default.
• W1996716984 hasConcept C203014093 @default.
• W1996716984 hasConcept C2776330855 @default.
• W1996716984 hasConcept C2777292125 @default.

• next